This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Salim, M. A. Articles by Di Sessa, T. G. Search for Related Content PubMed PubMed Citation Articles by Salim, M. A. Articles by Di Sessa, T. G.

CLINICAL RESEARCH: CLINICAL TRIALS

Effectiveness of fludrocortisone and salt in preventing syncope recurrence in children

A double-blind, placebo-controlled, randomized trial

Division of Pediatric Cardiology, Department of Pediatrics, the University of Tennessee, Memphis, Tennessee

Manuscript received December 4, 2003; revised manuscript received October 28, 2004, accepted November 2, 2004.

^* Reprint requests and correspondence: Dr. Mubadda A. Salim, 22 South Greene Street, Room N5W40, Baltimore, Maryland 21201 (Email: msalim{at}peds.umaryland.edu).

OBJECTIVES: We sought to evaluate the effectiveness of salt and fludrocortisone versus placebo in the prevention of syncope recurrence in children.

BACKGROUND: Intravascular volume expansion with fludrocortisone and salt has been reported to be effective in the treatment of syncope in children. However, no pediatric placebo-controlled data are available on the effectiveness of this mode of therapy.

METHODS: Thirty-three children with syncope or severe presyncope were randomized in a double-blinded fashion to receive either fludrocortisone 0.1 mg/day and salt 1 g/day or placebo two capsules per day for one year. All children had a positive tilt test before enrollment.

RESULTS: Thirty-two children (20 female) had follow-up. Their age was (mean ± SD) 13.9 ± 2.5 years. The number of syncopal episodes before therapy was 4.4 ± 4.8. Therapy was continued for 176 ± 117 days, and follow-up including time after discontinuation of medications was 1.2 ± 0.8 years. The demographics were similar in the 18 children treated with fludrocortisone and salt compared with the 14 children on placebo. Data for up to one year of randomization were included in analyses. Symptoms recurred in 10 of 18 children on fludrocortisone and salt and in 5 of 14 children on placebo (p < 0.04). Children on placebo had no symptoms until they discontinued their study medications.

CONCLUSIONS: These data, coupled with the reported comparable effect of many medications used in the treatment of syncope, raise the potential of a significant placebo effect with pharmacologic therapy.

Abbreviations and Acronyms   BP = blood pressure   NaCl = sodium chloride

This article has been cited by other articles:

				B Yeung and K McLeod The implantable loop recorder in children Heart, July 1, 2008; 94(7): 888 - 891. [Abstract] [Full Text] [PDF]

				M. P. Tan and S. W. Parry Vasovagal syncope in the older patient. J. Am. Coll. Cardiol., February 12, 2008; 51(6): 599 - 606. [Abstract] [Full Text] [PDF]

				A. Bell and K. McLeod Not so funny turns Arch. Dis. Child. Ed. Pract., February 1, 2007; 92(1): ep7 - ep13. [Full Text] [PDF]

				D. Danford Salt and Fludrocortisone Not Effective for Recurrent Syncope AAP Grand Rounds, June 1, 2005; 13(6): 62 - 62. [Full Text] [PDF]